Adipotide
Also known as: FTPP, Prohibitin-Targeting Peptide
Molecular Identifiers
Overview
Synthetic peptide that combines a vascular targeting sequence with a pro-apoptotic domain (FTPP). Designed to selectively target the white adipose tissue vasculature, inducing apoptosis in endothelial cells supplying fatty tissue.
Adipotide takes an unusual approach to fat loss: rather than modulating metabolism or appetite, it induces apoptosis in endothelial cells supplying white adipose tissue, leading to fat tissue reabsorption through vascular deprivation. In non-human primates this mechanism produced significant weight loss over a few weeks of treatment.
The peptide remains experimental and has no regulatory approval from any agency. Dose-dependent nephrotoxicity has been observed in preclinical studies, making renal monitoring a minimum requirement in any protocol. Access is restricted to research-use suppliers; in clinical settings it is dispensed off-label only sparingly and under supervision, given a safety profile that is still being evaluated.
It was developed at the MD Anderson Cancer Center (University of Texas) by the team of Wadih Arap and Renata Pasqualini, originally as a vascular biology tool before being studied as an anti-obesity approach.
CKGGRAKDCGGKLAKLAKKLAKLAK Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys-Gly-Gly-D(Lys-Leu-Ala-Lys-Leu-Ala-Lys-Lys-Leu-Ala-Lys-Leu-Ala-Lys) Conjugated peptide — vascular homing sequence (CKGGRAKDC) fused with pro-apoptotic sequence (KLAKLAK)₂
Half-life
~30 minutes
Administration Route
Subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- Binding to prohibitin on the vascular endothelial surface of adipose tissue
- Internalization and release of the pro-apoptotic domain D(KLAKLAK)2
- Induction of apoptosis in endothelial cells of adipose vessels
- Disruption of blood supply to white adipose tissue
- Reabsorption of fatty tissue through vascular deprivation
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 0.03 mg/kg body weight (Phase 1 trial starting dose) |
| Frequency | Once daily |
| Timing | Same time each day |
| Duration | Single 28-day cycle (NCT01262664 trial) |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Dehydration
- Fatigue
- Transient proteinuria
- Injection site pain
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 2 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Adipotide found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 1-2 ml per vial
- Slowly inject the diluent along the vial wall
- Gently swirl until fully dissolved — never shake
- Calculate dose based on body weight
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 14 days)
- Protect from direct light
- Do not freeze after reconstitution
- Limited stability after reconstitution
Scientific Studies
Published studies on Adipotide.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
AICAR
0.1 mg/kg/min by intravenous infusion (CABG trial dose) · Single continuous infusion
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly
Exenatide
5-10 mcg per injection (subcutaneous) · Twice daily (Byetta) or once weekly (Bydureon)